---
title: "Repository-Clinical"
description: "Anything that helps my learning into the topics."
hideBackToTop: false
hidePagination: true
---
[2021_08_NEJM: Empagliflozin in Heart Failure with a Preserved Ejection Fraction](https://www.nejm.org/doi/full/10.1056/NEJMoa2107038)\
Empagliflozin use in HFpE. 

[2022_11_Lancet: Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial](https://doi.org/10.1016/S0140-6736(22)02083-9)\
IV Iron use in HFrEF.

[2005_05_NEJM: Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis](https://www.nejm.org/doi/full/10.1056/NEJMoa050516)\
Infliximab induction. [Mayo Score for UC](https://www.mdcalc.com/calc/3675/mayo-score-disease-activity-index-dai-ulcerative-colitis)

[2015_04_NEJM: Prednisolone or Pentoxifylline for Alcoholic Hepatitis](https://www.nejm.org/doi/full/10.1056/NEJMoa1412278)\
Pentoxifylline did not improve survival in patients with alcoholic hepatitis.

[2002_07_Gastroenterology: Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding: A randomized, controlled, double-blind trial](https://doi.org/10.1053/gast.2002.34230)\
IV Erythromycin before emergency endoscopy improves quality of endoscopy

[2007_08_Clinical_Infectious_Diseases: A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity](https://doi.org/10.1086/519265)\
Vancomycin and Metronidazole equally effective in C.diff infection

[2010_04_NEJM: Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease(SONIC)](https://www.nejm.org/doi/full/10.1056/NEJMoa0904492)

[2008_02_Lancet: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial](https://doi.org/10.1016/S0140-6736(08)60304-9)\
Infliximab and azathioprine combination better than monotherapy with steroids

[2007_06_Ann_Intern_Med: Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab](10.7326/0003-4819-146-12-200706190-00159)\
Adalimumab as second agent when infliximab non-responding

[2019_09_NEJM: Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis](10.1056/NEJMoa1905725)\
Vedolizumab superior to adalimumab (but not corticosteroid-free clinical remission)



| Study Name | Author and Year | Type of Study and Sample Size       | Treatment and Duration    | Study Endpoint and Primary Outcome | Results                      |
| ---------- | --------------- | ----------------------------------- | ------------------------- | ---------------------------------- | ---------------------------- |
| Study 1    | Author A (2020) | Randomized Controlled Trial (n=100) | Drug A, 6 months          | Endpoint X, Outcome Y              | Significant improvement in Y |
| Study 2    | Author B (2019) | Cohort Study (n=200)                | Treatment B, 1 year       | Endpoint Z, Outcome W              | No significant change in W   |
| Study 3    | Author C (2021) | Case-Control Study (n=150)          | Intervention C, 3 months  | Endpoint Y, Outcome Z              | Outcome Z improved by 15%    |
| Study 4    | Author D (2018) | Cross-Sectional Study (n=250)       | Lifestyle change, 6 weeks | Endpoint A, Outcome B              | Minor improvement in B       |
| Study 5    | Author E (2022) | Meta-Analysis (n=10 studies)        | Various, Duration varies  | Endpoint C, Outcome D              | Overall positive trend in D  |
